Sector News

Latest Allergan buzz puts Ireland’s Jazz in its dealmaking sights

September 8, 2014
Life sciences
Forget Salix Pharmaceuticals and long-gone Shire. No. 1 on Allergan’s list of defensive acquisition prospects could be Ireland’s Jazz Pharmaceuticals.
 
The Dublin drugmaker is the most viable option for Allergan, which hopes a pickup of its own will thwart a hostile takeover attempt from Valeant, three industry bankers told dealReporter (as cited by Benziga).
 
Jazz, with its tax-advantaged Irish address, could be the lifeline Allergan’s been looking for. Analysts have long said bulking up could help the Botox-maker fend Valeant off, and a lowered tax rate would negate one of the proposed benefits of a merger with the Canadian drugmaker.
 
That’s not to mention Jazz’s own merits, which include some of the best profit margins in the drug industry. The tiny company has been beefing itself up lately, too; in December it paid $1 billion to buy Italy-based Gentium in a deal analysts said could make Jazz a more attractive target.
 
But plenty of rumors have been flying since CEO J. Michael Pearson’s deal machine made its first bid for Allergan this spring. First in the spotlight was Ireland’s Shire, which AbbVie quickly moved in to snap up in July. More recently, a potential move for North Carolina’s Salix had industry-watchers abuzz.
 
And to say Jazz is a rumor-mill regular would be an understatement. The specialty pharma, which makes the narcolepsy treatment Xyrem, has long made the list of pharma’s perennial takeover targets, though so far, it’s survived pharma’s tax inversion frenzy.
 
Still, speculation fueled a 7% rise in Jazz’ stock price Friday, and thanks to Ireland’s buyout rules, it may not be long before we know if the two parties really are engaged in M&A talks.
 
As Sterne Agee analyst Shibani Malhotra wrote in a note to clients, the Irish Takeover Panel’s rules require that an announcement regarding the offer be made in the event of an “anomalous movement in share price.”
 
“In our view there should be further clarity in the next few business days with either a disclosure confirming takeover talks or a lack of an announcement following what appears to be an Irish Takeover Panel disclosure triggering event,” he wrote.
 
By Carly Helfand
 

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach